{
    "code": "02023539",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02023539",
    "time": "2020-02-25 13:09:14",
    "許可證字號": "衛署藥輸字第023539號",
    "註銷狀態": "已註銷",
    "註銷日期": "105\/05\/24",
    "註銷理由": "許可證已逾有效期",
    "有效日期": "101\/08\/29",
    "發證日期": "91\/08\/29",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202353902",
    "中文品名": "雅瑞 輸注液",
    "英文品名": "AGGRASTAT INJECTION PREMIXED",
    "適應症": "AGGRASTAT併用HEPARIN，可用於預防不穩定心絞痛病人或非Q波之心肌梗塞病人發生缺血性心臟併發症，及用於預防患有冠狀動脈缺血症狀而須接受冠狀動脈成形術或冠狀動脈粥狀硬化切除的病人發生治療冠狀動脈突然閉塞時所造成的缺血性心臟併發症。",
    "劑型": "270注射劑",
    "包裝": "250公撮塑膠軟袋裝 1小袋盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": [
        ""
    ],
    "藥品類別": "05限由醫師使用",
    "藥品分類": "",
    "主製造廠": {
        "限制項目": "02輸　入 1Q不得輸入",
        "申請商名稱": "0929301100  美商默沙東藥廠股份有限公司台灣分公司",
        "申請商地址": "台北市信義區信義路五段106號12樓",
        "主製造廠": ""
    },
    "CCC號列": "30049099904 其他醫藥製劑〈不包括第３００２、３００５或３００６節所列者〉包含經混合或未混合產品供治療或預防疾病用，具有劑量（包括經皮給藥形態者）或零售包裝式樣者Other medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200038210",
            "成分名稱": "TIROFIBAN HYDROCHLORIDE MONOHYDRATE",
            "含量描述": "",
            "含量": "0.0561800000",
            "單位": "MG"
        }
    ]
}